Boehringer's zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, Germany
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 ( ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
The application for this investigational treatment is based on positive results from the Phase Ib Beamion LUNG-1, Cohort 1 trial that demonstrated an objective response rate of 71% in 75 previously treated patients with advanced NSCLC
HER2 ( ERBB2)-mutant advanced NSCLC is linked to poor prognosis and currently has limited treatment options1
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2) mutations and who have received prior systemic therapy. The FDA grants Priority Review to applications for drugs that would offer significant improvements in the treatment, diagnosis, or prevention of serious conditions, with action expected within six months compared to 10 months under standard review. The Prescription Drug User Fee Act (PDUFA) action date is in the third quarter of 2025.
'We believe zongertinib has the potential to transform the care of previously treated patients with HER2 (ERBB2) -mutant advanced non-small cell lung cancer and are hopeful about the continued research in other tumor types and lines of therapy,' said Shashank Deshpande, Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. 'Priority Review illustrates the urgent need in this patient population and the possibility for zongertinib to be a groundbreaking innovation for patients with limited treatment options.'
The application was based on results from the positive Phase Ib Beamion LUNG-1 trial. Data from Cohort 1 (N=75) of the study, demonstrated an objective response rate (ORR) of 71% with six-month progression-free survival (PFS) and duration of response (DoR) rates of 69% and 73%, respectively, in patients with mutations in the HER2 tyrosine kinase domain.
Zongertinib had a safety profile with a low incidence of dose reductions (5%) and treatment discontinuations (3%). The majority of treatment-related adverse events (TRAEs) with zongertinib were mild in nature with diarrhea and rash being the most common all grade TRAEs, at 51% and 27% respectively. No new safety signals were observed. Grade 3 or higher TRAEs occurred in one patient treated with zongertinib. No treatment-related interstitial lung disease (ILD) cases were reported.
'Personalized medicine has revolutionized cancer treatment,' said GO2 for Lung Cancer's Chief Scientific Officer, Courtney Granville. 'Early screening and biomarker testing for mutations provide critical information to guide targeted therapies in personalized medicine. This filing acceptance represents a significant step toward offering another option for individuals with a HER2 ( ERBB2) diagnosis, bringing hope and direction to cancer patients.'
Zongertinib was previously granted Breakthrough Therapy Designation and Fast Track Designation by the FDA. The FDA's Breakthrough Therapy designation is intended to expedite the development and review of a medicine that is intended to treat a serious or life-threatening disease, and preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available treatments. The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. In addition to the FDA designations, Japan's Pharmaceuticals and Medical Devices Agency recently granted Orphan Drug Designation to zongertinib.
About the Beamion clinical trial program
Beamion LUNG-1 ( NCT04886804) is an open-label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib as monotherapy in people with unresectable or metastatic solid tumors with HER2 ( ERBB2) alterations. Beamion LUNG-2 is a Phase III, open label, randomized, active-controlled study that is enrolling patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 ( ERBB2) tyrosine kinase domain mutations to evaluate zongertinib compared with standard of care.
About zongertinib
Zongertinib (also known as BI 1810631) is an investigational, irreversible tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 ( ERBB2) while sparing EGFR, thereby limiting associated toxicities. This orally administered, targeted treatment is being developed for HER2 ( ERRB2) - mutant advanced non-small cell lung cancer (NSCLC) and additional clinical studies with zongertinib are ongoing in solid tumors with HER2 alterations.
About non-small cell lung cancer (NSCLC)
Lung cancer claims more lives than any other cancer type and the incidence is set to increase to over 3 million cases worldwide by 2040.2 NSCLC is the most common type of lung cancer.3 Due to a lack of symptoms and misdiagnoses,4 most patients diagnosed with NSCLC present at stage III or IV, where the disease has metastasized locally or to other organs.5 Fewer than 3 in 10 patients are alive five years after a diagnosis of HER2 ( ERBB2)-mutant advanced NSCLC.6 People living with advanced NSCLC can experience a detrimental physical, psychological, and emotional impact on their daily lives. There remains a high unmet need for additional treatment options for people living with advanced NSCLC. HER2 ( ERBB2) mutations occur in approximately 2–4% of NSCLC cases and are associated with a poor prognosis and higher incidence of brain metastases.7,8 Mutations in HER2 ( ERBB2) can lead to overexpression and overactivation, which can in turn result in uncontrolled cell production, inhibition of cell death and promotion of tumor growth and spread.9
About Boehringer Ingelheim in oncology
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Boehringer Ingelheim's generational commitment to driving scientific innovation is reflected by the company's robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. Boehringer's ambition in oncology is to take a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com/us.
1Nützinger J, Lee JB, Low JL, et al. Lung Cancer. 2023;186:107385. doi:10.1016/j.lungcan.2023.107385
2International Agency for Research on Cancer – World Health Organization. Rates of trachea, bronchus and lung cancer. Available at: https://gco.iarc.fr/tomorrow/en (Accessed: January 2025).
3Zappa C & Mousa Non-small cell lung cancer: current treatment and future advances, Transl Lung Cancer Res. 2016 Jun; 5(3): 288–300.
4American Cancer Society. Signs and Symptoms of Lung Cancer Available at: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/signs-symptoms.html (Accessed: January 2025).
5Casal-Mouriño, A. et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506-518.
6National Cancer Institute Surveillance, Epidemiology, and End Results (SEER). https://seer.cancer.gov/statfacts/html/lungb.html (Accessed: January 2025).
7Baraibar I, et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit Rev Oncol Hematol. 2020;148:102906.
8Li, B.T. et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. N Engl J Med. 2022;386:241–51.
9Galogre M, et al. A review of HER2 overexpression and somatic mutations in cancers, Critical Reviews in Oncology/Hematology, Volume 186, 2023, 103997
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella
In a June news release, the U.S. Food and Drug Administration revealed that "brown cage-free and brown certified organic eggs" from the August Egg Company have "the potential" to be contaminated with salmonella. The outlet added that the eggs were "sold under multiple different brand names at restaurants and retailers" and should "no longer be available for sale." Those brands are Clover, First Street, Nuaid, O Organics, Marketside, Raleys, Simple Truth, Sun Harvest, and Sunnyside. According to People, over 1.7 million eggs have been recalled in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. On June 6, 2025, the Centers for Disease Control and Prevention revealed they were investigating the "multi-state outbreak of salmonella infections." Mayo Clinic states that while some people with salmonella may have no symptoms, most experience a range of symptoms, like abdominal cramps, within 8 to 72 hours. "In some cases, diarrhea can cause severe dehydration and requires prompt medical attention. Life-threatening complications also may develop if the infection spreads beyond the intestines. The risk of getting salmonella infection is higher with travel to countries without clean drinking water and proper sewage disposal." At this time, 21 people have been hospitalized due to infection, according to the FDA. In a statement, the August Egg Company shared, "We believe it is appropriate out of an abundance of caution to conduct this voluntary recall, as consumers may still have these eggs in their homes. It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." The company concluded, "We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again."FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella first appeared on Men's Journal on Jun 7, 2025
Yahoo
6 hours ago
- Yahoo
Salmonella outbreak causes egg recall; 79 people sick
(WTVO) — An egg producer based in California is recalling over a million eggs across nine states due to a salmonella outbreak, according to the (FDA). The specific type of eggs recalled was cage-free brown eggs manufactured by the August Egg Company. Those eggs were sold between February 3 and May 15. Select Walmart locations had the tainted eggs for sale, including stores in Illinois. They are also being recalled at Save Mart, FoodMaxx, Lucky, Smart & Final, Food 4 Less, Smart and Final, Safeway, Raleys and Ralphs. from the U.S. Centers for Disease Control and Prevention show that 79 people fell ill and 21 people went to the hospital in seven states. The specific container had a plant code number of P-6562 or CA5330 printed on the package. Salmonella infections can happen 12 to 72 hours after eating food that is contaminated. Symptoms of Diarrhea, fever and abdominal cramps can last from four to seven days, according to the . Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
7 hours ago
- Yahoo
Food recall: Brown eggs sold at grocery stores across California have salmonella risk
A California company is recalling 1.7 million cartons of brown eggs — sold at stores including Walmart in nine states including California — because the eggs may be contaminated with salmonella bacteria. August Egg Company of Hilmar is recalling 1,700,000 dozen brown cage-free and brown certified organic eggs for potential salmonella risk. The eggs were distributed over the last four months, some with sell by dates as late as June 19, according to the recall notice from the Food and Drug Administration. The eggs are linked to an ongoing Salmonella Enteritidis outbreak in seven states, in which 79 people have been sickened and at least 21 hospitalized, but no deaths have been reported, according to the Centers for Disease Control and Prevention. Most of the people sickened (63) live in California, according to the CDC. Nevada and Washington reported four illnesses each, with additional cases in Arizona (3), New Jersey (2), Nebraska (2), Kentucky (1). Ill people in Kentucky, New Jersey, and Washington reported traveling to California and Nevada before they got sick. Most of those sickened (90%) reported eating eggs, the CDC said. Some samples taken by the FDA during an inspection at August Egg Company's processing facility tested positive for the strain of salmonella similar to those related to the persons sickened in the outbreak, the CDC said. August Egg Co. said its internal food safety team is conducting its own investigation to "identify what measures can be established to prevent this situation from recurring," the company said in a statement accompanying the recall. 'It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." USA TODAY Recall Database: Search vehicle, product and food recalls The recalled eggs were distributed beginning Feb. 3 across multiple retailers in nine states: Eggs with sell-by dates to June 4: Through May 15, eggs with those sell-by dates were distributed to Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less and Ralphs stores in California and Nevada. Eggs with sell-by dates to June 19: Through May 6, eggs with those sell-by dates were distributed to Walmart locations in California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana and Illinois. August Egg Co. said consumers can identify the recalled eggs by the plant code on one side of the egg carton. They can return the eggs to the place of purchase for a refund. Consumers with questions can call the company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT. Here's the products recalled with plant code and UPC. Salmonella causes about 1.35 million illnesses, 26,500 hospitalizations, and 420 deaths each year in the U.S., according to the CDC and FDA. Symptoms of salmonella infection – including diarrhea, fever and stomach cramps – typically arise six hours to six days after exposure and may last 4 to 7 days. Severe infections can also include aches, headaches, elevated fever, lethargy, rashes, and blood in the urine or stool. Salmonella poisoning, also known as salmonellosis, is a common gastrointestinal infection in California, with about 5,000 confirmed cases annually, according to the California Department of Public Health. The Centers for Disease Control estimates that around 3,000 people die from a foodborne illness, and of those about 420 people die from Salmonella infections. This article originally appeared on Palm Springs Desert Sun: Egg recall 2025: Salmonella risk for eggs sold at California stores
